Kite Pharma’s Post

Having a great discussion about post CDK4/6 treatment option in MBC in the era of precision medicine, discussing the most important resistant mechanism of endocrine therapy and the new emergent treatment options for patient with hormonal receptor positive HER2 negative metastatic breast cancer Great panel Aydah AlAwadhi Dina Hamza Paolo Tarantino

Exciting news for the community of patients, healthcare professionals, and #precisionmedicine advocates! A new study has been published in the oncology journal Cancer Medicine: "𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗿𝗲𝗴𝗮𝗿𝗱𝗶𝗻𝗴 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: 𝗔 𝘀𝗰𝗼𝗽𝗶𝗻𝗴 𝗿𝗲𝘃𝗶𝗲𝘄" 📈 This research explores how we can improve communication around personalized cancer care between patients and providers regarding biomarker testing in precision oncology: https://lnkd.in/dR7pmbWE 𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝘀𝗵𝗮𝗿𝗲 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝘆𝗼𝘂𝗿 𝗻𝗲𝘁𝘄𝗼𝗿𝗸, 𝘀𝗼 𝘄𝗲 𝗰𝗮𝗻 𝗯𝘂𝗶𝗹𝗱 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝗮 𝘀𝘁𝗿𝗼𝗻𝗴𝗲𝗿 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝗿-𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝘀𝗵𝗮𝗿𝗲𝗱 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗺𝗮𝗸𝗶𝗻𝗴 𝗶𝗻 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲! 🙏 A special thanks to the authors who contributed to this publication: Theresia Pichler, Friederike Mumm, Navdeep Dehar MBBS MD MBT CCRP FRCPC, Erin Dickman DNP, RN, OCN, Celia Diez de los Rios, Andreas Dinkel, Kathrin Heinrich, Merel Hennink, Anndra D. Parviainen, Amy C. Moore, PhD.

📣Today, we celebrate International Clinical Trials Day, a day dedicated to highlighting the crucial role of research in advancing medical treatments. We share the story of Ana María, a 79-year-old from Buenos Aires, Argentina, who is participating in a clinical trial investigating new treatment options for muscle-invasive bladder cancer 👏 Share your thoughts or experiences in the comments below. #ClinicalTrialsDay #BladderCancerResearch #BladderCancer #BladderCancerMonth24

Did you know that 64% of patients with advanced non-small-cell lung cancer aren’t receiving the precision therapies they need? As precision medicine evolves, integrating biomarker testing into clinical care remains a significant challenge. Learn about the key barriers and how we can overcome them to improve patient outcomes. https://lnkd.in/gtuQ6xVh #PersonalizedMedicine #PrecisionMedicine #PrecisionOncology #CancerCare

🚨 Major Collaboration Update! Precision for Medicine is working with SOPHiA GENETICS and Boundless Bio to revolutionize clinical trials with their novel platform. Precision for Medicine helped validate a novel assay to enable advanced diagnostic workflows for Boundless Bio’s POTENTIATE trial, expediting patient selection for ecDNA-driven cancer therapies. Read more about the partnership and breakthrough on the Precision for Medicine press release! https://hubs.ly/Q02QJ09Q0? #precisionmedicine #clinicaltrials #datadrivenmedicine #SOPHiAGenetics #BoundlessBio

Please read about the promising results from the first cohort of three patients in our Deltacel-01 Phase 1 clinical trial at Beverly Hills Cancer Center. "Consistency in safety, tolerability, and disease stability is of paramount importance at this stage of testing, and the data thus far bolster our confidence in Deltacel's potential as a transformative treatment," stated Pietro Bersani, Chief Executive Officer of Kiromic BioPharma. “The findings are especially promising considering the robustness of response in the absence of brain metastasis, and the notable reduction in tumor size for the second and the first patient, respectively." #cartcelltherapy #celltherapy #patientsfirst https://lnkd.in/eVycTBzU

📚 Your Weekly NICE Guideline Updates Got to https://whitecoat.ai for frequent AI generated summaries with links to full guidelines. Sign up for free to stay up to date! NICE Publication (Jan 10): Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer NICE Publication (Jan 10): Sebelipase alfa for treating Wolman disease #nhs #healthcare

Join Matthew Smeltzer, Associate Professor at the University of Memphis and 2024 Biomarker Survey Steering Committee Member, in shaping the future of lung cancer care: https://gather.video/WFmH. Take just 10 minutes to share your valuable insights in the ongoing international survey conducted by IASLC on biomarker testing practices. Your contribution as a researcher, clinician, or advocate is crucial in improving patient outcomes. Take action today and make a difference! TAKE THE SURVEY: https://bitl.ly/BMS24

Theralase Technologies (TSXV: TLT) CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive #BladderCancer clinical study during an interview with Steve Darling from Proactive. DuMoulin-White shared the significant findings from the study, revealing that it has provided the primary study treatment to 63 patients. The interim clinical data from Study II shows promising results, with a Complete Response (CR) rate of 54% at 6 months, 38% at 12 months, and 37% at 15 months. These CR rates surpass the guidelines set by the International Bladder Cancer Group (IBCG). Additionally, at the 90 Day Assessment Visit, 56% of Evaluable Patients achieved a CR, and 63% achieved a Total Response (CR + IR). At 450 days, 37% achieved a CR, and 41% achieved a TR. Watch at #Proactive #ProactiveInvestors #TSXV #OTCQB #TLT #TLTFF http://ow.ly/YLin10598yw

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome With Teclistamab Administration - I'm please to announce this newly published Between the Lines Cancer Network program I had the opportunity to work on with my dear colleague Bing Xu. In this program Sagar Lonial, MD, FACP and Ellen Marin, PA-C discuss the abstract "Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome With Teclistamab Administration," recently presented at ASH 2023 and provide insights into findings and their impact on clinical practice. https://lnkd.in/gVUAXEcz Abstract --> https://lnkd.in/gyZAkCZt #CRS #CytokineReleaseSyndrome #Tocilizumab #teclistamab #ASH2023